Prospective study of relevance of I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

Date publication

juin 2018

Journal

Journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NAMER Izzie-Jacques

Tous les auteurs :
Alves Do Rego C, Namer IJ, Marcel C, Lefebvre F, Lagha-Boukbiza O, Renaud M, Tranchant C, Anheim M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29956027

Résumé

I-MIBG myocardial scintigraphy and clonidine growth hormone test (CGH test) may help to distinguish multiple system atrophy (MSA) from Parkinson's disease (PD). Their relevance in the first-stage parkinsonism of uncertain etiology is unknown.

Mots clés

3-Iodobenzylguanidine, Biomarkers, blood, Clonidine, blood, Diagnosis, Differential, Female, Follow-Up Studies, Heart, diagnostic imaging, Humans, Male, Middle Aged, Multiple System Atrophy, diagnosis, Parkinson Disease, diagnosis, Prospective Studies, Radionuclide Imaging, Radiopharmaceuticals, Sensitivity and Specificity

Référence

J. Neurol.. 2018 Jun 28;: